Highlights on the Luspatercept Treatment in Thalassemia
Luspatercept has been shown to act as a ligand trap, selectively suppressing the deleterious effects of GDF11 that blocks terminal erythroid maturation, restoring normal erythroid differentiation and improving anemia in animal models of β-thalassemia. Effective doses of luspatercept achieved hemoglo...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Thalassemia Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2039-4365/13/1/8 |